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Abstract
Background: Interest in psychological factors in patients with inflammatory bowel disease (IBD)
has increased in recent years. It has even been proposed that treating psychological co-morbidities
with antidepressants may control disease activity and improve quality of life. Despite this, there is
no data on gastroenterologists' attitudes to, and experiences with, antidepressant therapy in
patients with IBD.
Methods: We conducted semi-structured interviews with 18 gastroenterologists associated with
metropolitan teaching hospitals. Qualitative content analysis was used to examine their responses.
Results:  Seventy-eight percent of gastroenterologists had treated IBD patients with
antidepressants for pain, depression and/or anxiety, and insomnia. Antidepressants were reported
to be useful in improving psychosocial well-being, quality of life, and self-management of the disease
by patients. However, in this group of gastroenterologists, there appears to be skepticism towards
psychological disorders themselves or antidepressant therapy having a central role in either the
causation of IBD or its clinical course. Nevertheless, these gastroenterologists were receptive to
the idea of conducting a trial of the role of antidepressants in IBD.
Conclusion: While the majority of specialists have treated IBD patients with antidepressants,
there is considerable skepticism with regard to efficacy of antidepressive therapy or the role of
psychological factors in the outcome of IBD patients.
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Background
Inflammatory bowel disease (IBD) is a term used to
describe chronic, relapsing and remitting disorders of the
gastrointestinal tract that are characterized by inflamma-
tory changes of the gut wall and thought to be caused by
an inappropriate immune response. The two common
types of IBD are Crohn's disease (CD) and ulcerative coli-
tis (UC). The prevalence of IBD has been estimated at
43,000 in Australia [1].
Like the majority of chronic diseases, IBD carries a physi-
cal, economic and social burden for sufferers but, perhaps
most importantly; it also has serious psychological impli-
cations. Anxiety, depression and poor quality of life are all
predictors of worse medical outcomes in many chronic
conditions [2-5]. Moreover, psychological status is known
to independently impact quality of life [6]. In general, the
rate of common psychological disorders, such as depres-
sion and anxiety, is higher in chronically ill people than in
the wider population and has been estimated at about
30% [7,8]. It is conceivable that in at least some of the
chronically ill people the dual diagnoses (a somatic and a
psychological problem) are etiologically distinct and each
requires treatment on its own merits. Accurate diagnosis
of depression becomes important because of the likely
need for either effective drug therapy or a combination of
drug therapy with psychotherapy. Treatment of depres-
sion is particularly important in light of its association
with both medical noncompliance [9] and suicide
[10,11].
It is not well understood whether it is as a consequence of
their chronic disease or perhaps also from side effects of
medication, IBD patients often suffer from psychological
disorders that may, in turn, affect their response to stand-
ard treatment for IBD [2]. Patients who are diagnosed
with both IBD and psychological disorders have been
noted to have lower quality of life and more frequent
relapses [2,12]. In addition to psychological disorders,
patients with IBD are frequently also affected by irritable
bowel syndrome (IBS) [13]. IBS is a chronic condition in
which altered bowel habits and abdominal pain or dis-
comfort are the predominant symptoms in the absence of
any mechanical, infectious, biochemical or inflammatory
changes in the gastrointestinal tract [14] using standard
diagnostic tests. From 42% – 62% of CD patients and
33% of UC patients in remission suffer from IBS
[13,15,16]. Quality of life and psychosocial well-being in
these patients are therefore impaired regardless of
whether their IBD is active or quiescent [17]. Moreover, as
many as 93% of patients with IBS have a lifetime history
of some psychiatric disorder [18].
For approximately 30 years, researchers have examined
the effectiveness of various treatments for psychological
disorders in IBD patients, although unfortunately much
of this research is reported outside mainstream medical
journals. In summary, this literature reveals that psycho-
therapy is in general ineffective in treating psychological
disturbances in IBD patients, despite several different
modalities having been applied [19]. However, pharma-
cotherapy with antidepressants, either as an alternative or
adjunct to psychotherapy, has not yet been adequately
explored (12). Nonetheless, some early reports of its effi-
cacy in reducing both psychological and somatic symp-
toms, although unproven at present, seem promising
[20]. Further research into the influence of antidepres-
sants on the course of both CD and UC is therefore impor-
tant, especially that antidepressants have been found to
have a positive effect on symptoms and well-being of peo-
ple with IBS [21]. However, before the larger sample stud-
ies take place, qualitative investigations exploring
different aspects of this problem are highly recom-
mended.
As one of the major barriers to implementing a change in
disease management is the attitudes and habits of relevant
clinicians, we sought to conduct a qualitative exploratory
study into clinicians' views and practices on the use of
antidepressants in IBD. The semi-structured interviews
were designed to: 1) identify gastroenterologists' attitudes
to the use of antidepressants in IBD; 2) investigate gastro-
enterologists' observations of the effects of antidepres-
sants on IBD; and 3) explore gastroenterologists' attitudes
towards further research in this area, especially towards
possible randomized controlled trials.
Methods
Data for this exploratory study were collected in October
and November 2005 in two major South Australian met-
ropolitan teaching hospitals, the Royal Adelaide Hospital
(RAH) and the Queen Elizabeth Hospital (QEH). The
study used purposive sampling where participants were
selected based on their potential to provide data relevant
to the research questions [22]. All participants were board
recognized gastroenterologists with more than 2 years of
professional experience as a specialist. None had any for-
mal training in psychiatry. Interviews were conducted
until the interviewer was satisfied that data saturation
occurred. The researcher advertised the study during
research meetings at the Department of Gastroenterology,
Hepatology and General Medicine, at the RAH in Septem-
ber 2005 and at the Department of Gastroenterology and
Hepatology, at the QEH in October 2005 and invited cli-
nicians to indicate their willingness to participate. At the
beginning of each interview each participant signed a writ-
ten consent.
Digitally-recorded, standardized semi-structured inter-
views with 12 open-ended questions were undertakenBMC Gastroenterology 2007, 7:38 http://www.biomedcentral.com/1471-230X/7/38
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with each gastroenterologist by the first author (AM-W).
Demographic data were collected at the end of each inter-
view. The interviews lasted up to half an hour with a
median of 10 minutes. The recorded interviews were tran-
scribed verbatim by the first author (AM-W). The draft of
each interview was subsequently read and checked against
the recordings by a research assistant. No major areas of
disparity arose. Responses to each question were then col-
lected and summarized by AM-W. Where it was appropri-
ate to do so, responses were enumerated. Finally, AM-W
confirmed the general organisation of data and their inter-
pretation with NM.
Data were analyzed by qualitative content analysis [22].
The words and sentences relevant to the given question
were identified by AM-W. Responses to questions were
assigned to mutually exclusive categories where possible
and subsequently coded by AM-W. Participants' responses
were then summarized.
Ethical approval was obtained from the Royal Adelaide
Hospital Human Research Ethics Committee. Each partic-
ipant provided written informed consent.
Results
Eighteen participants were recruited. Nine gastroenterolo-
gists participated at each site. Two Gastroenterologists
associated with these departments did not participate due
to their direct involvement in the study (JMA & GJH). This
sample thus represents 78% (18 out of 23) of gastroenter-
ologists working in these two hospitals, 66% (18 out of
27) of all the gastroenterologists working in the Central-
Northern Adelaide Health Services, and 36.7% (18 out of
49) of all the gastroenterologists working in South Aus-
tralia. Seventeen of the 18 participants were male, which
is consistent with the gender mix for gastroenterologists in
SA. Ten were born outside Australia. Their ages ranged
from 33 to 64, with a median of 44. Their experience in
gastroenterology ranged from two to 30 years, with a
median of 16 years. Fifteen doctors completed their
undergraduate studies in Australia. Ten doctors com-
pleted their postgraduate studies in Australia, five con-
ducted them partly in Australia and partly abroad, and
three completed postgraduate studies abroad. Participants
reported treating between one and 12 IBD patients per
week (with a mean of five patients).
The role of antidepressants in IBD
All participants agreed that antidepressants were a useful
medication for depression, IBS and various pain syn-
dromes. The gastroenterologists often used antidepres-
sants in chronically ill people due to the high prevalence
of depression in this group. Two gastroenterologists
believed antidepressants were overused, yet another two
believed them to be underused. All participants were in
agreement that antidepressants cannot be used as effective
primary therapy in IBD and that no evidence exists in pub-
lished research that antidepressants have an influence on
the level of inflammatory markers. Most gastroenterolo-
gists, however, reported having successfully used antide-
pressants as an adjunct therapy. Interestingly, some
gastroenterologists stated that psychological problems in
IBD are easy to overlook and that in a number of patients,
psychological issues are a significant concern.
Reasons for using/not using of antidepressants in patients 
with IBD
Fourteen of eighteen participants had prescribed antide-
pressants or suggested using antidepressants in IBD
patients. Reasons given for treating IBD patients with anti-
depressants were: pain, evidence of depression or signifi-
cant mood disorder, which might include anxiety,
depression, sleep problems, and gut symptoms despite
being in quiscent phase (gut irritablity, IBS in IBD). Seven
out of 14 gastroenterologists who had prescribed antide-
pressants had specifically treated depression or anxiety
with antidepressants. Most (12 out of 14) of the partici-
pants who prescribed antidepressants to IBD patients,
however, prefered referring depressed patients to their GP
or to psychiatrist rather than being the initiators of this
treatment. On the other hand, gastroenterologists felt
comfortable with using antidepressants for pain, dis-
turbed sleep patterns, and IBS symptoms in IBD. Those
gastroenterologists who did not use antidepressants in
IBD patients reported that this was either because they
had not treated a depressed patient; did not believe
depression was a significant problem in these patients; or
did not see their role as detecting depression.
The kind of antidepressants used and the result of the 
treatment
Participants had used classic tricyclics (e.g. amitriptyline,
dothiepin, prothiaden, doxepin, imipramine, nortriptyl-
ine), selective serotonin reuptake inhibitors (SSRI) (cita-
lopram, sertraline), and serotonin and noradrenaline
reuptake inhibitors (SNRI) (mirtazapine) antidepressants
in patients with IBD. However, with tricyclics they
reported mainly focusing on treating somatic aspects of
the disease e.g. pain, gut irritability, urgency of defecation.
Tricyclics are, according to most of the participants, better
researched in this area and have been found to be effective
for IBS-like symptoms in IBD patients. Gastroenterolo-
gists often reported using the same antidepressants that
they prescribe in patients with IBS. Only a few had tried
treating depression and/or anxiety in their IBD patients
with the newer antidepressive agents. Those who had used
the newer agents felt that psychological problems
responded well to this treatment.BMC Gastroenterology 2007, 7:38 http://www.biomedcentral.com/1471-230X/7/38
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The treatment with antidepressants and the course of IBD
Ten of the 14 gastroenterologists who had prescribed anti-
depressant therapy did not perceive that antidepressants
had any influence on the course of IBD. However, one of
them explained his opinion in a following way: "I don't
think it influences the activity of the IBD. The IBD is
occurring in an individual and the individual's ability to
manage the disease can clearly be improved by managing
the accompanying mood disorder". Despite their opposi-
tion to the idea that antidepressants directly affect the
course of the disease, many argued that the treatment with
antidepressants seemed to improve patients' quality of
life. In general, antidepressants were thought to help IBD
patients in manage their disease, cope with unpleasant
symptoms, improve patients' sleep patterns, reduce pain
and gut irritability and help them look after their nutri-
tion and diet. Moreover, the benefits of the treatment with
antidepressants might be more visible on disease activity
indices rather than on inflammatory activity markers. Two
gastroenterologists who thought treatment with antide-
pressants had influenced the course of IBD reported that
antidepressants helped in controlling exacerbations of
IBD and reduced symptoms of IBD. These two gastroen-
terologists used amitriptyline, nortriptyline, citalopram,
and sertraline.
Most participants who had used antidepressants in IBD
patients (12 out of 14) believed that there was no differ-
ence in the effect of antidepressants on the disease
between CD and UC patients. However, three doctors
noticed that they mainly had treated CD patients with
antidepressants, and not UC. One participant hypothe-
sized that this was because of the earlier onset of CD com-
pared to UC. In general, CD patients seemed to be treated
with antidepressants for their psychological problems and
pain whereas UC patients for pain and sleep disturbances.
Nevertheless, the tendency was not very strong, as most
participants did not differentiate between CD and UC in
terms of their co-occurrence with depression and/or anxi-
ety.
Psychological treatments in IBD patients
Nine of 18 participants reported suggesting psychological
treatment for their IBD patients. Some gastroenterologists
reported that they referred their patients to psychologists,
counselors, psychiatrists or general practitioners for psy-
chotherapy. One doctor revealed he conducted some form
of psychotherapy himself with his patients. Gastroenterol-
ogists also suggested hypnotherapy, relaxation and physi-
cal exercises to IBD patients. Gastroenterologists reported
that they sought psychological treatment for their IBD
patients when patients had symptoms of depression and/
or anxiety; had chronic pain syndrome; psychosexual
problems and problems with body image; or were opioid-
dependent. The results of these treatments were, however,
by and large unknown, as the gastroenterologists did not
specifically follow up the patients with respect to psycho-
logical co-morbidities.
Gastroenterologists' opinion on the feasibility of a trial 
with antidepressants in IBD patients
All 18 gastroenterologists said they would approve of their
IBD patients' decision to enter a trial of antidepressant
therapy as long as it was a properly conducted double
blind randomized controlled trial.
Discussion
This qualitative exploratory study was designed to investi-
gate and describe the attitudes and practices of specialist
gastroenterologists with respect to antidepressant and
other psychological therapies in patients with IBD. Based
upon this study, gastroenterologists are well aware of a
high burden of anxiety and depression in IBD patients,
although they do not routinely evaluate their patients for
psychological co-morbidities. Many are open to the
premise that treating anxiety and depression may improve
patients' quality of life. The participants were, however,
quite skeptical that  psychological disorders and/or anti-
depressant therapy had a central role in the  clinical course
of IBD.
Although it is controversial, some investigators have pro-
posed that the psyche may play a pivotal role in the cau-
sation of IBD [23-25], whilst others have proposed that
psychological co-morbidities, especially anxiety and
depression, may influence the clinical course of IBD [2].
As yet, the literature is unable to answer the question as to
whether treatment of IBD with antidepressant therapy is
of benefit [20], mostly due to the quality of available data:
non-randomized, non-blinded, and non-controlled stud-
ies. However, antidepressants have been found to have
anti-inflammatory properties by influencing production
of anti-inflammatory cytokines [26,27]. There is also evi-
dence that stress may trigger exacerbation of IBD by
inducing pro-inflammatory responses [28] and that
depression and anxiety may lead to more frequent
relapses of IBD [2]. However, no trial devoted solely to the
use of antidepressants in IBD has ever been conducted.
Thus, one of the main aims of this investigation was to
assess gastroenterologists' likely acceptance of a properly
conducted clinical trial in this area. Indeed, the content
analysis revealed that although the interviewed gastroen-
terologists used antidepressants in IBD to minimize
symptoms and to treat insomnia, anxiety and depression,
they would require strong evidence of specific benefit
prior to accepting them as having a role in modifying the
course of IBD.
In previous works on anxiety and depression in IBD, cer-
tain antidepressants have been suggested to have a specificBMC Gastroenterology 2007, 7:38 http://www.biomedcentral.com/1471-230X/7/38
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benefit on the clinical course of IBD [29-33]. Unfortu-
nately, none of gastroenterologists participating in the
current study had used these antidepressants, which
included paroxetine [29,33], bupropion [30,32] and
phenelzine [31]. As the interviewed gastroenterologists
were unable to confirm, or refute, the previously reported
observations, the choice of an antidepressant for the eval-
uation in future trials is still unclear. Taking into account
the opinions of the surveyed gastroenterologists, future
research into the role of antidepressants in IBD should
focus on both physical and psychological impact of anti-
depressants on IBD patients. If antidepressant therapy
were shown to improve the clinical course of IBD further
questions would need to be addressed. If all antidepres-
sants were equally effective, one may infer that the psyche
plays a major role in the course of IBD. On the other
hand, if a specific antidepressant (or class of antidepres-
sants) were more efficacious, our understanding of the
inflammatory cascade in IBD itself may change. Future
studies may, therefore, involve fairly complex designs
with sub-group stratification and multiple arms as well as
they would need to specify whether antidepressants are
prescribed for IBD itself, for mood only or for pain related
problems. Moreover, such studies could benefit from
inclusion of a psychiatrist into a research team and
research comparing the way gastroenterologists and psy-
chiatrists prescribe antidepressants in patients with IBD
could also be of interest.
Interestingly, during this study we also observed that
some gastroenterologists had treated IBD patients with
antidepressants in the same way they had treated IBS
patients. This is not surprising given the symptomatic sim-
ilarities of these two conditions [15] and the increasingly
well documented overlap between these two diseases
[13]. Twenty years ago IBS was thought to be a predomi-
nantly psychological condition with no inflammatory ele-
ment, whereas we now have some evidence of
pathological abnormalities in the gut [34,35]. By contrast,
IBD is currently thought to be purely inflammatory, how-
ever, clinical observations in individual patients render it
difficult to completely exclude psychological factors [36],
and even the "objective" measures of severity such as the
Crohn's Disease Activity Index (CDAI) are well known to
be affected by the psyche by influencing ratings for
"abdominal pain" and "general wellbeing". Moreover, as
IBD and IBS commonly coexist, it is difficult to make cat-
egorical distinctions between psychological versus inflam-
matory mechanisms. It is, therefore, very important to
explore various treatment options in the hope that
informed discussion will prompt further research and
improve standard medical care of these patients and thus,
their quality of life. The fact that these surveyed gastroen-
terologists generally endorsed the concept of conducting a
properly designed trial on the role of antidepressants in
IBD and would encourage their patients to participate in
such research is an important result in this regard.
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